1 (800) 227-9902

Key Features

  • Lowest crossing profile
  • Greatest maximum expansion in small diameter sizes
  • Up to 5.5 mm expansion to treat large vessels
  • Better pushability and flexibility in complex anatomy
  • Best-in-class safety & efficacy profile

Abbott Vascular has received FDA approval for the XIENCE Sierra drug-eluting stent (DES). The device introduces Slim Flex Technology, allowing the stent to be crimped tighter and resulting in the lowest crossing profile on the market. Delivery system innovations improve the device’s pushability and flexibility in challenging anatomy, while a new implant design allows XIENCE Sierra to reach 5.5 mm expansion in the 3.5 and 4.0 mm diameter sizes for the treatment of large vessels. XIENCE Sierra also maintains the best-in-class safety and efficacy profile of the XIENCE family of DES.

“We developed XIENCE Sierra so that physicians can more easily deliver the stent even in challenging cases,” said Chuck Brynelsen, Senior Vice President of Abbott’s vascular business. “The updated design and improved deliverability mean doctors can access and unblock difficult-to-treat lesions with more flexibility and precision than other stents.”

The XIENCE Sierra DES is available for use in the European Union, Japan, and the United States.


Contact Info

For advertising rates and opportunities, contact:
Craig McChesney

Stephen Hoerst

Charles Philip

About Cardiac Interventions Today

Cardiac Interventions Today (ISSN 2572-5955 print and ISSN 2572-5963 online) is a publication dedicated to providing comprehensive coverage of the latest developments in technology, techniques, clinical studies, and regulatory and reimbursement issues in the field of coronary and cardiac interventions. Cardiac Interventions Today premiered in March 2007 and each edition contains a variety of topics in a flexible format, including articles covering various perspectives on current clinical topics, in-depth interviews with expert physicians, overviews of available technologies, industry news, and insights into the issues affecting today's interventional cardiology practices.